TransCon Growth Hormone: Additional Phase II data

Ascendis said top-line data from an open-label, international Phase II trial in 53 treatment-naive patients ages 3-12 with GHD showed that once-weekly 0.14, 0.21 and 0.3 mg/kg subcutaneous TransCon Gr...